Safety and Effectiveness of TaurusTrio™ Heart Valve System in Patients With Severe Aortic Regurgitation (AR)

NARecruitingINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2029

Conditions
Aortic Regurgitation
Interventions
DEVICE

TaurusTrio™ Heart Valve System

The TaurusTrio™ Heart Valve System contains the following sub-components: a prosthetic transcatheter porcine pericardial aortic valve, 20Fr Introducer Sheath System, transfemoral Delivery Catheter, and Loading Tool.

Trial Locations (19)

215025

RECRUITING

Beijing Anzhen Hospital, Beijing

Unknown

RECRUITING

Fu Wai Hospital, Beijing, China, Beijing

RECRUITING

Fujian Medical University Union Hospital, Fuzhou

RECRUITING

XiaMen Cardiovascular Hospital XiaMen University, Xiamen

RECRUITING

Guangdong Provincial People's Hospital, Guangzhou

RECRUITING

Nanfang Hospital, Southern Medical University, Guangdong

RECRUITING

The Second Affiliated Hospital of Harbin Medical University, Haerbin

RECRUITING

Renmin Hospital of Wuhan University, Wuhan

RECRUITING

Wuhan Union Hospital, China, Wuhan

RECRUITING

Second Xiangya Hospital of Central South University, Changsha

RECRUITING

Nanjing First Hospital, Nanjing

RECRUITING

The First Affiliated Hospital of Namchang Umiversity, Nanchang

RECRUITING

General Hospital of Northern Theater Command, Shenyang

RECRUITING

Qilu Hospital of Shandong University, Jinan

RECRUITING

Shanghai Zhongshan Hospital, Shanghai

RECRUITING

Xijing Hospital, Xian

RECRUITING

West China Hospital, Chengdu

RECRUITING

Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

RECRUITING

Sir Run Run Shaw Hospital of Zhejiang, Hangzhou

All Listed Sponsors
lead

Peijia Medical Technology (Suzhou) Co., Ltd.

INDUSTRY